Uveitic macular edema: Pathophysiology and treatment update
Journal of Clinical and Experimental Ophthalmology

Journal of Clinical and Experimental Ophthalmology
Open Access

ISSN: 2155-9570

Uveitic macular edema: Pathophysiology and treatment update

5th International Conference on Clinical & Experimental Ophthalmology

August 04-06, 2015 Valencia, Spain

Rola N Hamam

Scientific Tracks Abstracts: J Clin Exp Ophthalmol

Abstract :

Purpose: To review the epidemiology, risk factors and pathophysiology of uveitic macular edema and discuss advances in
diagnosis and treatment.
Methods: Review of the literature and presentation of case series of the use of topical bromfenac for the treatment of uveitic
macular edema, also discussion of the effect of intravitreal adalimumab on uveitic macular edema.
Results: Advanced age and chronic edema are among the poor prognostic factors. 11 patients (14 eyes) treated with bromfenac
0.09% daily. Median CRT improved from 427 to 257 (p=0.002). 8/10 eyes had resolution of SRF. 6/11 eyes had resolution of
CME. Median logMar improved from 0.39 to 0.17 (p=0.3) and 6/14 eyes gained more than 2 lines. 1.5 mg adalimumab injected
intravitreally every month for active noninfectious uveitis. 5/8 eyes had resolution of macular edema. Median time to resolution
was 6 weeks (range: 2-26). Median CRT improved from 317 mm to 277 mm at 6 months (p=0.021).
Conclusion: Uveitic macular edema is a cause of significant loss of vision in patients with uveitis. Treatment modalities include
non steroidal anti-inflammatory medications, corticosteroids, immune modulatory therapies, anti vascular endothelial growth
factors and diuretics.

Biography :

Rola Hamam is an Assistant Professor of Ophthalmology at the American University of Beirut. She is the Director of the residency training program and the medical retina
fellowship training program. She received her BS degree in biology from the American University of Beirut in 1998 and her MD in 2002. She completed her residency in
Ophthalmology at the same institution then had fellowship training at Harvard University in Boston at the Beetham Eye Institute, the Massachusetts Eye and Ear Infirmary,
and the Massachusetts Eye Research and Surgery Institution with Doctor C Stephen Foster until 2008. She returned to her home country and joined her Alma matter in
2009 to start the first uveitis specialty referral clinic in the country at the American University of Beirut. She is a member of several national and international societies. She
has organized and lectured on ocular immunology and uveitis in many national and international conferences and scientific meetings. She is involved in multiple research
projects on ocular inflammatory and infectious disease and she continues to contribute scientific publications in the field.